About us

We are Perosphere Technologies

Perosphere Technologies

We are changing the way decisions are made in coagulation. We enable a paradigm shift by making diagnosis, treatment, and prevention a matter of actionable data, immediately accessible to all.

Sense of Clarity

Sense of Confidence

Sense of Comfort

Leadership

Sasha H. Bakhru, PhD

President, Chief Executive Officer

Sasha H. Bakhru, PhD

Dr. Bakhru is a Founder of Perosphere Inc. (now Perosphere Technologies Inc. and Perosphere Pharmaceuticals Inc.), an Adjunct Assistant Professor of Medical Science at Brown University, and Lecturer in Entrepreneurship.

He is a member of the Scientific Advisory Board of Amylyx Pharmaceuticals. Dr. Bakhru has co-authored over 30 publications, ten patents, and one book chapter. His work has been published in 40 conference proceedings and abstracts. Dr. Bakhru received a BS in Biomedical Engineering from Columbia University, an MSE from Johns Hopkins University in Materials Engineering, and a PhD from Carnegie Mellon University in Biomedical Engineering as a Dowd Fellow in the Institute for Complex Engineered Systems. He was winner of the 2008 Global MOOT Corp competition, and in 2009, received the Carnegie Mellon Tepper School of Business “Entrepreneur of the Year” and “Manufacturing Entrepreneur of the Year” alumni prizes.

Alan Curtis

Vice President, Regulatory Affairs

Alan Curtis

Mr. Curtis has over 30 years experience in the medical device industry, specifically in Regulatory Affairs, Quality Systems, and Clinical Affairs.

He has provided regulatory strategies and submissions for multiple medical device disciplines and projects and has designed clinical studies to support many of these submissions. Internationally, Mr. Curtis has created Technical Files to support the CE Mark, prepared successful submissions to Health Canada, and several Pacific Rim countries. Mr. Curtis has held a variety of senior management positions including Director and Vice President in the Regulatory Affairs, Clinical, and Quality Systems areas of responsibility at companies including W.L. Gore and Associates, Viveve Medical, Aragon Surgical, and Reliant Technologies. He received a B.Sc in Microbiology and Regulatory Affairs Certification (RAC).

Xuan Jiang, PhD

Executive Vice President, Research

Xuan Jiang, PhD

Dr. Xuan Jiang joined Perosphere Inc. in 2012 and served as VP, Pre-Clinical Development supporting ciraparantag, a novel anticoagulant reversal agent, at Perosphere Pharmaceuticals Inc. from 2014 until 2018.

Dr. Jiang received his BS in Polymer Science and Engineering from Fudan University in 2001, MSE in Chemistry from National University of Singapore, and PhD degree in Materials Science and Engineering in 2010 from Johns Hopkins University. Dr. Jiang completed postdoctoral training at the Institute for NanoBioTechnology at Johns Hopkins in 2012. Dr. Jiang has co-authored 24 journal publications, 12 conference presentations, one book chapter, and 2 US patents. Dr. Jiang has served as reviewer for several scientific journals including Biomaterials, Pharmaceutical Research, Biomacromolecules, and International Journal of Nanomedicine.

Raymond R. Mandra, JD

Patent Counsel

Raymond R. Mandra, JD

Mr. Mandra is a former partner of the intellectual property law firm of Fitzpatrick, Cella, Harper & Scinto, where he practiced for 28 years out of their New York office.

He was also chair of the firm’s biotechnology group for more than a decade. Representative clients of Mr. Mandra, while in private practice, included Allergan PLC, Astellas Pharma Inc., Bristol-Myers Squibb, Genzyme, Leo Pharma Inc., Mars Incorporated, Novartis, Pfizer, Sanofi, and Warner Chilcott. Prior to entering the private practice of law, Mr. Mandra worked for nine years as a chemist for the General Foods Corporation. Mr. Mandra received his J.D., magna cum laude in 1990 from Pace University School of Law, where he was the Research and Writing Editor on the Pace Law Review. He also has an M.S. in Chemistry from Long Island University and a B.S. in Chemistry from the State University of New York at Oswego.

Daryl Mootoo

Executive Vice President and Chief Operating Officer

Daryl Mootoo

Mr. Mootoo has 10 years experience helping drive commercial sales via strategic planning and sales operational excellence.

At Icahn Enterprises, he assessed the long-term viability of at-risk revenue streams in portfolio holdings, and helped to mitigate risk through new product offerings, divestiture, or other strategic alternatives. At both AMEX and Gartner, Mr. Mootoo helped unlock additional revenue by addressing productivity gaps and driving operational consistency.

Steve Ward

Executive Vice President and Chief Financial Officer

Steve Ward

Mr. Ward has extensive experience in the medical device industry and venture capital, with expertise in accounting/manufacturing operations, systems enhancements, strategic planning and analysis.

He is critically effective in developing financial systems technology to meet increasingly complex corporate requirements. Mr. Ward has held CFO/COO positions at various organizations including Viscogliosi Bros., Paradigm Spine, Small Bone Innovations.and ITC. Early experience includes time at Howmedica Stryker and KPMG.

Board of Directors

Sasha H. Bakhru, PhD

President, Chief Executive Officer

Sasha H. Bakhru, PhD

Dr. Bakhru is a Founder of Perosphere Inc. (now Perosphere Technologies Inc. and Perosphere Pharmaceuticals Inc.), an Adjunct Assistant Professor of Medical Science at Brown University, and Lecturer in Entrepreneurship.

Michelle Brennan

Board Member

Michelle Brennan

Ms. Brennan has over three decades of healthcare leadership, specializing in regulatory affairs, clinical trials, market access, and global commercialization of medical devices.

In her former role as Company Group Chair of Medical Devices at Johnson & Johnson, she led initiatives that prioritized patient safety, comfort, and well-being while facilitating the growth of the division. Ms. Brennaan has held various leadership positions at Johnson & Johnson, including former President of Enterprise Standard & Productivity, and prior to that served as Worldwide President for Ethicon Energy, where she established a strategic leadership team to explore innovative opportunities and shape product development. Ms. Brennan currently sits on the Board of Directors of Cardinal Healthcare and Masimo.

Kevin Crowley

Board Member

Kevin Crowley

Kevin Crowley is a senior managing director of investments at Connecticut Innovations.

He has led investments in Convexity Scientific, Origen Pharmaceuticals, Affinmark Technologies, Cara Therpeatuics (IPO), CaroGen Corporation, Discover VIdeo, HistoRx ( sold to Genoptix), Intelligent Clearing Network, Oil Purification Systems, Oxford Performance Materials, Perosphere, Precipio Diagnostics (IPO), Solais Lighting (sold to PowerSecure), MinInvasive Orthopedics Solutions, OmniCyte, VeraDermics, and Point Pickup. Kevin managed CI's $46 million BioFacilities Fund, which invested in wet laboratory space for bioscience companies, and managed CI's two incubators laboratories in Science Park in New Haven. Kevin was also involved in the establishment of the Connecticut Stem Cell Fund and managed CI's pre-seed program, which makes investments in veery early-state companies with smaller convertible-debt instruments.

Mark Pavao

Board Member

Mark Pavao

Mark Pavao has been a commercial leader in the global biopharma industry for 30+ years.

He currently supports developing biotech companies with commercial and go-to-market strategy and tactical planning. Previous roles include President and CEO of R-Pharm US, President Bristol-Myers Squibb (BMS) / AstraZeneca Diabetes Alliance, President Emerging Markets Region at BMS, and SVP of Global Market Access and Pricing at BMS. Earlier, Mark held sales and marketing leadership roles at Bristol-Myers Squibb, SmithKline Beecham Pharmaceuticals, NitroMed Inc., and HeliosHealth.

Solomon Steiner, PhD

Chairman of the Board

Solomon Steiner, PhD

Dr. Steiner founded and served as CEO to three publicly-traded drug-delivery companies: Biodel Inc., MannKind Corp., and Emisphere Technologies, Inc. Dr. Steiner served as Biodel’s Chairman, President and Chief Executive Officer from its inception in December 2003 through March of 2010.

In 1991, Dr. Steiner founded Pharmaceutical Discovery Corporation ("PDC"), a biopharmaceutical corporation and is an inventor of its Technosphere™ Technology and MedTone™ Inhaler. Dr. Steiner served as PDC’s Chief Executive Officer and Chairman of the board of directors from its inception until December 2001, when PDC was merged with two other companies to form MannKind Corporation. In 1985, Dr. Steiner founded and was Chairman of the board and President of Clinical Technologies Associates, Inc. ("CTAI"), now known as Emisphere Technologies, Inc. Under his leadership, CTAI went public in February of 1989. Dr. Steiner was elected a Fellow of the American Psychological Association in 1973 for his work in psychopharmacology and has authored or co authored over 200 scientific publications. Dr. Steiner received a BA from New York University with a major in psychology and chemistry, and a PhD from New York University.

Advisory Board

Jack E. Ansell, MD

Chair

Jack E. Ansell, MD

Jack E. Ansell, MD is the former Michael S. Bruno, MD, Chairman of Medicine at Lenox Hill Hospital and current Professor of Medicine at New York University School of Medicine. Dr. Ansell is a clinical investigator with a principal focus on the clinical problems of thrombosis, antithrombotic therapy, and the application of new modes of delivering and monitoring anticoagulants.

He has authored more than 200 publications and has been the lead author for over 10 years of the major authoritative consensus guidelines for antithrombotic therapy through the American College of Chest Physicians. He is a Master of the American College of Physicians. Dr. Ansell received his medical degree from the University of Virginia and completed his medical residency at Tufts New England Medical Center, followed by a fellowship in Hematology at Boston University.

Harvey Cantor, MD

Advisor

Harvey Cantor, MD

Harvey Cantor, MD is Chair, Department of Cancer Immunology & AIDS and Baruj Benacerraf Professor of Microbiology and Immunobiology, Harvard Medical School. Dr. Cantor joined the Dana Farber Cancer Institute and Harvard faculty in 1974. Since 1997, he has chaired the Department of Cancer Immunology and AIDS, and directed the DF/HCC Program in Cancer Immunology.

He engages in teaching/training within the Harvard Medical School Graduate Program in Immunology and directs NIH postdoctoral training programs in AIDS research and cancer immunology. Dr. Cantor trained at the National Institutes of Health and National Institute for Medical Research in London. He received an MD from New York University in 1967 and completed residency in medicine at Stanford. In 2002, Dr. Cantor was elected to the U.S. National Academy of Sciences.

S. Thomas Emerson, PhD

Advisor

S. Thomas Emerson, PhD

S. Thomas Emerson, PhD is David T. and Lindsay J. Morgenthaler Professor of Entrepreneurship at the Carnegie Mellon Tepper School of Business. Dr. Emerson is an experienced entrepreneur, corporate executive, and educator.

He founded and built three venture capital backed high technology companies: Periphonics Corporation, Syntellect Inc., and Xantel Corporation. Two of these companies (Periphonics and Syntellect) became NASDAQ-listed national market companies. They created in aggregate more than $600 million in shareholder value. Dr. Emerson was named Inventor of the Year by the U.S. Patent Office in 1973. Prior to joining Carnegie Mellon, he was President and CEO of Arizona Technology Incubator, a public-private partnership in Scottsdale, Arizona that mentors promising young technology companies.

Robert S. Langer, Jr. ScD

Advisor

Robert S. Langer, Jr. ScD

Dr. Robert Langer is a leading bioengineer and entrepreneur. He is one of 11 Institute Professors at the Massachusetts Institute of Technology, the highest honour that can be awarded to a faculty member.

Prior to this role, he was the Germeshausen Professor of Chemical and Biomedical Engineering. Langer is an internationally acclaimed inventor and engineer, with over 2000 patents and published articles. His research focuses on the field of bioengineering. He was one of the first chemical engineers to work in the surgical sector, becoming a pioneer in drug delivery, tissue engineering, and nanotechnology. Langer’s research laboratory at MIT is the largest academic biomedical engineering lab in the world, maintaining over $15 million in annual grants and over 100 researchers. Langer is also currently on the board of directors at Bind Therapeutics and Advanced Cell Technology.

Michele Mercuri, MD

Advisor

Michele Mercuri, MD

Michele F. Mercuri, MD, PhD, FAHA, FESC, is a physician scientist professionally devoted to fostering the discovery, research, translation, and development of innovative diagnostic, prophylactic, and therapeutic medical tools.

A former Daiichi Sankyo Sr. Vice President, Dr. Mercuri led the development of edoxaban—an oral, direct factor Xa inhibitor. Dr. Mercuri served as the Global Head for cardio, vascular, metabolic and renal disease Therapeutic Area for translational sciences and clinical development, Chief Medical Advisor to the Head of Development, and Head of Clinical Development for the Americas. Dr. Mercuri graduated in medicine and surgery from the University of Perugia (Italy), and trained in Internal and Geriatric Medicine at the Universities of Parma (Italy) and Modena (Italy). A fellow in Cerebrovascular Disease and Vascular Ultrasound at the Bowman Gray School of Medicine at Wake Forest University (Winston-Salem, NC, USA), Dr. Mercuri served on the Medical School Faculty and as the Co-Director of the Division of Vascular Ultrasound. Dr. Mercuri joined the Pharmaceutical Industry with Merck Research Laboratory (Rahway, NJ, USA) in 1996 and worked on a wide range of cardiometabolic drugs in all phases of research and development. In 2003, Dr. Mercuri moved to Novartis Pharmaceuticals’ Clinical Development & Medical Affairs (East Hanover, NJ, USA) to lead Cardiometabolic Disease and Atherosclerosis drug development prior to assuming leading positions within the Methodology and Innovation Global Development group, and in the Division of Hematology and Oncology. Dr. Mercuri published over 100 articles in peer-reviewed medical and scientific journals in collaboration with leading scientists from around the world.

Contact us

Perosphere Technologies

108 Mill Plain Road, Suite 301
Danbury, CT 06811

+1 (475) 218-4600

Careers

To find out the latest job opportunities, please contact us
careers@perospheretech.com

Investors

Get in touch about partnership or collaboration opportunities
investors@perospheretech.com

Info

For general inquiries please contact administration

info@perospheretech.com

Media

Get in touch for media inquiries or image requests

media@perospheretech.com